NCT07745504 — Overweight trial site landscape

Public-registry site landscape for NCT07745504, “A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight”, a Overweight study sponsored by Novo Nordisk A/S. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07745504 (registry record)
Study title	A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Official title	A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity
Sponsor	Novo Nordisk A/S
Condition(s)	Overweight; Obesity
Phase	PHASE3
Listed sites	36
Site countries	United States, Greece, Hungary, Portugal, Serbia, Sweden

Recruiting-density context

At Hope Clin Res & Wellness — one of the facilities listed on this trial — 3 other studies are actively recruiting Overweight patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.

Patient-friendly overview of this study: eichor.com/study/NCT07745504.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07745504 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →